Seattle-based Proprio, a startup using artificial intelligence to improve surgical precision, announced its second major clearance from the U.S. Food and Drug Administration to include measurements taken during operations.
Founded in 2016 and spun out of the University of Washington, Proprio combines computer vision, robotics, machine learning, and augmented reality to fuse high-definition images of the operating field with images of pre-operative 3D scans, leading to more accurate decisions in surgery. “Evolving from highly educated guesswork to data-driven certainty with intraoperative measurements is game-changing,” said Gabriel Jones, CEO and co-founder of Proprio, in a statement.
This milestone highlights the region’s strength at the convergence of biotech and AI, reinforcing Washington state’s leadership in developing next-generation health technologies to improve patient outcomes.